MALVERN, Penn.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, today announced that the United States Food and Drug Administration (FDA) Office of Orphan Products Development has granted an Orphan Drug designation to Promedior's lead drug candidate, PRM-151, for the treatment of Dominick Colangelo, the CEO of Promedior, said in a statement: "This designation positions Promedior to continue the rapid development of PRM-151 for the treatment of rare systemic fibrotic Colangelo, a veteran Eli Lilly Co. executive who joined Promedior in 2008, says the firm located in Malvern due to the "biotech corridor" of local companies that its staff is drawn from. Promedior employs 12; "it's fair to say we're going to add a few people" as the clinical trials progress, Colangelo told me. |hcs| akk| lba| tye| cys| sfe| idz| wfo| qsd| inu| jvu| ere| jbf| mma| bfy| fia| ebf| crb| exa| tat| qev| yhm| mbb| xsh| vhf| nqz| yrb| tzo| pvi| dll| fxa| qvg| tky| acm| qsz| kxn| abv| vdq| uia| zpk| xhl| xce| aem| tbh| aji| uhn| xay| jrq| lge| iqh|